Ask AI
ProCE Banner Activity

ALNEO: Phase II Trial of Perioperative Alectinib in Potentially Resectable Stage III ALK-Positive NSCLC

Conference Coverage
Slideset

In the phase II ALNEO clinical trial, neoadjuvant treatment with alectinib in patients with stage III ALK-positive NSCLC met the primary endpoint of improving major pathologic response in potentially resectable tumors with no unexpected safety signals.

Released: June 04, 2025

Expiration: December 03, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, and PharmaMar.

AstraZeneca

Boehringer Ingelheim Pharmaceuticals, Inc.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

PharmaMar